Prognostic significance of right ventricular hypertrophy and systolic function in Anderson-Fabry disease.
Anderson-Fabry disease
Prognosis
RV systolic function
RVH
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
25
11
2019
revised:
24
02
2020
accepted:
31
03
2020
pubmed:
21
5
2020
medline:
22
6
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
Right ventricular hypertrophy (RVH) is a common finding in Anderson-Fabry disease (AFD), but the prognostic role of right ventricular (RV) involvement has never been assessed. The aim of our study was to evaluate the prognostic significance of RVH and RV systolic function in AFD. Forty-five AFD patients (56% male patients) with extensive baseline evaluation, including assessment of RVH and RV systolic function, were followed-up for an average of 51.2 ± 11.4 months. RV systolic function was assessed by standard and tissue Doppler echocardiography. Cardiovascular events were defined as new-onset atrial fibrillation (AF), sustained ventricular arrhythmias, heart failure, or pacemaker/implantable cardioverter defibrillator implantation; renal events were defined as progression to dialysis and/or renal transplantation or significant worsening of glomerular filtration rate; and cerebrovascular events were defined as transient ischaemic attack or stroke. Fourteen patients (31.1%) presented RVH, while RV systolic function was normal in all cases. During the follow-up period, 13 patients (28.8%, 11 male) experienced 18 major events, including two deaths. Cardiovascular events occurred in eight patients (17.7%). The most common event was pacemaker/implantable cardioverter defibrillator implantation (six patients, 13.3%), followed by AF (three cases, 6.6%). Only one case of worsening New York Heart Association class (from II to III and IV) was observed. Ischaemic stroke occurred in three cases (6.6%). Renal events were recorded in three patients (6.6%). At univariate analysis, several variables were associated with the occurrence of events, including RVH (HR: 7.09, 95% CI: 2.17 to 23.14, P = 0.001) and indexes of RV systolic function (tricuspid annular plane systolic excursion HR: 0.77, 95% CI: 0.62 to 0.96, P = 0.02; and RV tissue Doppler systolic velocity HR: 0.76, 95% CI: 0.61 to 0.93, P = 0.01). At multivariate analysis, proteinuria (HR:8.3, 95% CI: 2.88 to 23.87, P < 0.001) and left ventricular mass index (HR: 1.02, 95% CI: 1.00 to 1.03, P = 0.03) emerged as the only independent predictors of outcome. RVH and RV systolic function show significant association with clinical events in AFD, but only proteinuria and left ventricular mass index emerged as independent predictors of outcome. Our findings suggest that RV involvement does not influence prognosis in AFD and confirm that renal involvement and left ventricular hypertrophy are the main determinant of major cardiac and non-cardiac events.
Identifiants
pubmed: 32432376
doi: 10.1002/ehf2.12712
pmc: PMC7373914
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1605-1614Informations de copyright
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
Références
Echocardiography. 2007 May;24(5):452-6
pubmed: 17456062
Int J Cardiol. 2016 Dec 15;225:177-183
pubmed: 27728861
Clin Kidney J. 2016 Oct;9(5):739-47
pubmed: 27679722
J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8
pubmed: 20620859
Eur J Heart Fail. 2013 Apr;15(4):408-14
pubmed: 23307814
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Cardiovasc Pathol. 2010 Sep-Oct;19(5):293-301
pubmed: 19631563
J Med Genet. 2015 May;52(5):353-8
pubmed: 25795794
Amyloid. 2016 Sep;23(3):158-167
pubmed: 27348696
Eur Heart J Cardiovasc Imaging. 2015 Jan;16(1):47-52
pubmed: 25187607
Rofo. 2011 Nov;183(11):1037-42
pubmed: 21959886
Eur J Heart Fail. 2007 Aug;9(8):808-13
pubmed: 17586091
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Eur Heart J Cardiovasc Imaging. 2012 May;13(5):416-22
pubmed: 22180463
J Am Soc Echocardiogr. 2008 Nov;21(11):1265-8
pubmed: 18835697
Heart. 2010 Dec;96(23):1915-9
pubmed: 20965976
Am J Cardiol. 2014 Jan 15;113(2):361-7
pubmed: 24230980
J Intern Med. 2013 Oct;274(4):331-41
pubmed: 23586858
Eur Heart J Cardiovasc Imaging. 2012 Aug;13(8):680-9
pubmed: 22307866
N Engl J Med. 1967 May 25;276(21):1163-7
pubmed: 6023233
Heart. 2007 Apr;93(4):528-35
pubmed: 17401074
J Am Coll Cardiol. 2011 Mar 1;57(9):1093-9
pubmed: 21349401
Can J Cardiol. 2015 Jun;31(6):702-8
pubmed: 25935883
J Am Soc Echocardiogr. 2017 Mar;30(3):282-291
pubmed: 28069318
Eur J Echocardiogr. 2010 Jan;11(1):51-6
pubmed: 19910319
Eur J Echocardiogr. 2000 Dec;1(4):281-8
pubmed: 11916607
Int J Cardiol. 2017 Dec 15;249:261-267
pubmed: 28964554
ESC Heart Fail. 2020 Aug;7(4):1605-1614
pubmed: 32432376
Circulation. 2003 Apr 22;107(15):1978-84
pubmed: 12668521
Eur Heart J. 2007 May;28(10):1228-35
pubmed: 17483538
Acta Paediatr Suppl. 2005 Mar;94(447):15-8; discussion 9-10
pubmed: 15895706
Clin Genet. 2004 Apr;65(4):299-307
pubmed: 15025723
Am J Cardiol. 2016 Aug 1;118(3):432-9
pubmed: 27289293